Roche Reports 17% Jump in Net Income for First Half of 2025
ByAinvest
Thursday, Jul 24, 2025 5:51 am ET1min read
MED--
Roche's Pharmaceuticals Division sales rose by 10% (6% in CHF), with key drivers including Phesgo (breast cancer), Xolair (food allergies), Hemlibra (haemophilia A), Vabysmo (severe eye diseases), and Ocrevus (multiple sclerosis) [1]. The Diagnostics Division sales were stable (-3% in CHF), as demand for pathology solutions and blood screening tests offset healthcare pricing reforms in China [1].
Core operating profit increased by 11% (6% in CHF) to 12.0 billion Swiss francs, driven by higher sales and effective cost management. Core earnings per share showed significant growth of 12% (8% in CHF) [1].
The company also announced several key approvals and positive data for various therapies, including Itovebi for advanced breast cancer, Evrysdi tablet for spinal muscular atrophy, and Susvimo for diabetic retinopathy [1]. Roche's CEO, Thomas Schinecker, noted the company's strong growth momentum and resilience, driven by its innovative on-market portfolio and pipeline.
The appreciation of the Swiss franc against most currencies had an adverse impact on results when reported in Swiss francs compared to constant exchange rates. However, the company expects an increase in Group sales in the mid single-digit range (CER) for 2025, with core earnings per share targeted to develop in the high single-digit range (CER). Roche also expects to further increase its dividend in Swiss francs [1].
References:
[1] https://www.roche.com/media/releases/med-cor-2025-07-24
Swiss pharmaceutical giant Roche reported a 17% increase in net income to 7.8 billion Swiss francs ($9.85 billion) in the first half of 2025, driven by strong sales of asthma and breast cancer treatments. Sales exceeded forecasts, rising 4% to 30.9 billion Swiss francs. The company confirmed its full-year outlook and advanced four potentially "practice-changing" drugs into the final stage of clinical development.
Swiss pharmaceutical giant Roche reported a 17% increase in net income to 7.8 billion Swiss francs ($9.85 billion) in the first half of 2025, driven by strong sales of asthma and breast cancer treatments. Sales exceeded forecasts, rising 4% to 30.9 billion Swiss francs. The company confirmed its full-year outlook and advanced four potentially "practice-changing" drugs into the final stage of clinical development.Roche's Pharmaceuticals Division sales rose by 10% (6% in CHF), with key drivers including Phesgo (breast cancer), Xolair (food allergies), Hemlibra (haemophilia A), Vabysmo (severe eye diseases), and Ocrevus (multiple sclerosis) [1]. The Diagnostics Division sales were stable (-3% in CHF), as demand for pathology solutions and blood screening tests offset healthcare pricing reforms in China [1].
Core operating profit increased by 11% (6% in CHF) to 12.0 billion Swiss francs, driven by higher sales and effective cost management. Core earnings per share showed significant growth of 12% (8% in CHF) [1].
The company also announced several key approvals and positive data for various therapies, including Itovebi for advanced breast cancer, Evrysdi tablet for spinal muscular atrophy, and Susvimo for diabetic retinopathy [1]. Roche's CEO, Thomas Schinecker, noted the company's strong growth momentum and resilience, driven by its innovative on-market portfolio and pipeline.
The appreciation of the Swiss franc against most currencies had an adverse impact on results when reported in Swiss francs compared to constant exchange rates. However, the company expects an increase in Group sales in the mid single-digit range (CER) for 2025, with core earnings per share targeted to develop in the high single-digit range (CER). Roche also expects to further increase its dividend in Swiss francs [1].
References:
[1] https://www.roche.com/media/releases/med-cor-2025-07-24
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet